Aline Valério de Lima
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aline Valério de Lima has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Jorge Luiz Mello Sampaio
Faculdade de Ciências Farmacêuticas da Universidade de São Paulo, São Paulo, SP, Brazil
2 shared publications - Darlan Augusto da Costa Rocha
Grupo Fleury, São Paulo, Brazil
1 shared publication - Eva M M Pariona
Unidad de Investigación de Enfermedades Emergentes y Cambio Climático, Universidad Peruana Cayetano Heredia , Lima
1 shared publication - Felipe Vásquez-Ponce
Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil
1 shared publication - Gustavo Fernandes Queiroga Moraes
Universidade Federal de Campina Grande
1 shared publication - Jesus G. M. Pariona
Department of Clinical Analysis, School of Pharmacy, University of São Paulo, São Paulo, Brazil
1 shared publication
Latest Publications
- 28 October 2024
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 80 (1) , 162-168
Efficacy of meropenem against ceftazidime–avibactam-resistant Klebsiella pneumoniae producing KPC-31, KPC-33, KPC-90, KPC-106 and KPC-114
Klebsiella pneumoniae producing KPC variants conferring resistance to ceftazidime–avibactam often remain susceptible to meropenem, suggesting a potential therapeutic use of this antibiotic. In this study, the efficacy of clinically relevant concentrations of meropenem was evaluated against high-risk clones of ceftazidime–avibactam-resistant K. pneumoniae strains producing KPC variants, in a tandem in vitro time-kill/in vivo Galleria mellonella survival model. In vitro/in vivo efficacy of meropenem against ceftazidime–avibactam-resistant K. pneumoniae of CG16, CG25 and CG258, producing KPC-31, KPC-33, KPC-90, KPC-106 and KPC-114 variants, was evaluated using EUCAST dosing recommendation adjusted to the G. mellonella model. For in vivo assays, untreated, meropenem (40 mg/kg × 1)-treated and ceftazidime–avibactam (40 mg/kg ceftazidime–10 mg/kg avibactam × 1)-treated groups were established, with 60 larvae per group. Kaplan–Meier curves, log-rank tests, univariate Cox regression and hazard ratios (HR) were used to assess treatment effects (P < 0.05). For all KPC-variant producers, time-kill assays showed >3 log-kills reduction (−6.91 ± 1.28 SD) after 6 h interaction when exposed to 8–32 mg/L meropenem MIC values (i.e. ≥ × 4 MIC). In the assessment of in vivo efficacy of meropenem, at the 4-day follow-up, mortality rates were 96.7% (untreated), 83.3% (ceftazidime–avibactam-treated) and 13.3% (meropenem-treated) (P < 0.05). Univariate Cox regression analysis showed significantly lower risk in the meropenem group compared to untreated group [HR 0.02 (95% CI: 0.01–0.05)]. These pre-clinical results might support use of meropenem as a potential alternative for treatment of infections due to KPC-variant producers displaying in vitro susceptibility to meropenem.
- 28 October 2024
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 80 (1) , 162-168
Efficacy of meropenem against ceftazidime–avibactam-resistant Klebsiella pneumoniae producing KPC-31, KPC-33, KPC-90, KPC-106 and KPC-114
Klebsiella pneumoniae producing KPC variants conferring resistance to ceftazidime–avibactam often remain susceptible to meropenem, suggesting a potential therapeutic use of this antibiotic. In this study, the efficacy of clinically relevant concentrations of meropenem was evaluated against high-risk clones of ceftazidime–avibactam-resistant K. pneumoniae strains producing KPC variants, in a tandem in vitro time-kill/in vivo Galleria mellonella survival model. In vitro/in vivo efficacy of meropenem against ceftazidime–avibactam-resistant K. pneumoniae of CG16, CG25 and CG258, producing KPC-31, KPC-33, KPC-90, KPC-106 and KPC-114 variants, was evaluated using EUCAST dosing recommendation adjusted to the G. mellonella model. For in vivo assays, untreated, meropenem (40 mg/kg × 1)-treated and ceftazidime–avibactam (40 mg/kg ceftazidime–10 mg/kg avibactam × 1)-treated groups were established, with 60 larvae per group. Kaplan–Meier curves, log-rank tests, univariate Cox regression and hazard ratios (HR) were used to assess treatment effects (P < 0.05). For all KPC-variant producers, time-kill assays showed >3 log-kills reduction (−6.91 ± 1.28 SD) after 6 h interaction when exposed to 8–32 mg/L meropenem MIC values (i.e. ≥ × 4 MIC). In the assessment of in vivo efficacy of meropenem, at the 4-day follow-up, mortality rates were 96.7% (untreated), 83.3% (ceftazidime–avibactam-treated) and 13.3% (meropenem-treated) (P < 0.05). Univariate Cox regression analysis showed significantly lower risk in the meropenem group compared to untreated group [HR 0.02 (95% CI: 0.01–0.05)]. These pre-clinical results might support use of meropenem as a potential alternative for treatment of infections due to KPC-variant producers displaying in vitro susceptibility to meropenem.
- Open Access
- 20 December 2021
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 28, 49-52
A simple disk pre-diffusion test to predict in vitro aztreonam/avibactam activity against NDM-producing Klebsiella pneumoniae complex
- 20 December 2021
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 28, 49-52
Open AccessA simple disk pre-diffusion test to predict in vitro aztreonam/avibactam activity against NDM-producing Klebsiella pneumoniae complex